Background-Glutathione S-transferases (GSTs) M1 and T1 detoxify products of oxidative stress and may protect against atherosclerosis and ischemic vascular disease (IVD). We tested the hypothesis that copy number variation (CNV) in GSTM1 and GSTT1 genes, known to be associated with stepwise decreases in catalytic activity, predict risk of IVD. Methods and Results-We included 23 059 Danes from 2 general population studies and 2 case-control studies, of whom 4930 had ischemic heart disease (IHD) and 2086 had ischemic cerebrovascular disease. A real-time polymerase chain reaction method genotyped for the exact number of GSTM1 and GSTT1 gene copies. We also performed meta-analyses, including our own and former studies, totaling 13 196 IHD cases and 33 228 controls. CNV in GSTM1 or GSTT1 or genotype combinations were not associated with an increased risk of IHD, myocardial infarction, ischemic cerebrovascular disease, ischemic stroke, or any ischemic vascular event in studies individually or combined or in the meta-analyses. Furthermore, genotypes did not interact with smoking on risk of disease end points. Finally, GST genotypes did not associate with markers of inflammation and oxidation or interact with smoking on markers of inflammation in the general population. In contrast, we observed the well-established association between CNV in GSTM1 and risk of bladder cancer. Conclusions-In studies including 6557 IVD cases and 16 502 controls and in meta-analyses of 13 196 cases and 33 228 controls, CNV in GSTM1 and GSTT1 genes did not associate with risk of IVD or with markers of inflammation. These observations were independent of smoking exposure. (Circ Cardiovasc Genet. 2011;4:418-428.)
and air pollution, thereby protecting the cell against xenobiotics and oxidative stress. 3 Two genes from the GST family, GSTM1 and GSTT1, show copy number variation (CNV) from 0 to 2 gene copies per allele per gene. GSTM1*0/0 and GSTT1*0/0 are associated with loss of catalytic activity, 4, 5 and a gene dosage effect between gene copy number and enzyme activity has been reported for both GSTM1 and GSTT1. 6 -8 The underlying hypothesis in epidemiological studies, therefore, is that CNV in GSTM1 and GSTT1 may modify risk of atherosclerosis because of altered protection against oxidative stress. 9 Because GSTs detoxify numerous toxic compounds and products of oxidative stress, they are good candidates for geneenvironment interactions, and CNV in GSTM1 and GSTT1 may modify the capacity of smoking to invoke inflammation and, hence, IVD. 9 Previous studies investigating the association of GST genotype with risk of IVD are mainly case-control studies incorporating a limited number of cases, and results have been inconsistent. 10 -32 None of these studies determined the exact number of gene copies but discriminated only between carriers (GST*1/0 plus GST*1/1 plus GST*2/1) and noncarriers (GST*0/0) of the genes. Furthermore, a potential modification by smoking status has been suggested but not addressed in studies with sufficient power. 11, 12, 17, 18, 20, 22, 24, 25, 27, 30, 32 Consequently, large studies with sufficient power to determine main as well as interaction effects of exact copy numbers of GSTM1 and GSTT1 are needed.
We examined the hypothesis that CNV in GSTM1 or GSTT1 associates with risk of ischemic heart disease (IHD), myocardial infarction (MI), ischemic cerebrovascular disease (ICVD), ischemic stroke (IS), or any ischemic vascular event and that GST genotype interacts with smoking exposure on disease end points. Similar hypotheses also were tested for 2 functional genetic variants in GSTP1, I105V (rs1695) and A114V (rs1138272).
Methods

Subjects
We studied white people of Danish descent. Studies were approved by institutional review boards and Danish ethical committees. Written informed consent was obtained from participants.
The Copenhagen City Heart Study
The Copenhagen City Heart Study (CCHS) is a prospective study of the general population initiated in 1976 to 1978, with follow-up examinations in 1981 to 1983, 1991 to 1994, and 2001 to 2003. [33] [34] [35] Individuals were randomly selected based on the national Danish Civil Registration System to reflect the adult Danish population aged 20 to Ն80 years. Data were obtained from a questionnaire, a physical examination, and blood samples. CNV in GSTM1 and GSTT1 was determined in 10 327 participants attending the 1991 to 1994 and 2001 to 2003 examinations. We excluded 110 individuals with IVD before study entry and 23 individuals with 3 gene copies, leaving 10 194 for all further analyses. Of these, 1769 developed IHD and 1031 developed ICVD. Follow-up started at study entry and ended at occurrence of event or July 9, 2007, whichever came first. Median follow-up time was 25 years and was 100% complete (ie, none were lost to follow-up). The online-only Data Supplement contains diagnostic criteria for IHD and ICVD.
The Copenhagen General Population Study
The Copenhagen General Population Study (CGPS) is a crosssectional study initiated in 2003 with ongoing enrollment. [33] [34] [35] Participants are recruited from the Danish general population and examined as in the CCHS. We included the first 9900 participants for the present study. Of these, 801 had IHD, and 450 had ICVD. Information on diagnoses of IHD and ICVD was ascertained like in the CCHS.
The Copenhagen Ischemic Heart Disease Study
The Copenhagen Ischemic Heart Disease Study (CIHDS) comprises 2360 patients from the greater Copenhagen area referred for coronary angiography to Copenhagen University Hospital during the period from 1991 through 2004. These patients had documented IHD based on characteristic symptoms of stable angina 36 plus at least 1 of the following: Ͼ50% diameter stenosis or diffuse atherosclerosis on coronary angiography, a previous MI, or a positive bicycle exercise electrocardiography test. The diagnosis of MI was established with the same criteria as in the CCHS and CGPS. The 2360 IHD cases were matched for sex and 1-year age strata with 4160 controls free of IVD from the CGPS.
The Copenhagen Carotid Stroke Study
The Copenhagen Carotid Stroke Study (CCSS) comprises 605 patients from the greater Copenhagen area referred for carotid artery ultrasonography to Copenhagen University Hospital in the period from 1994 through 2005. Experienced neurologists and vascular surgeons diagnosed ICVD on the basis of IS, transient ischemic attack, or amaurosis fugax together with at least 50% stenosis of a carotid artery. Hemorrhage was excluded on CT scan. The 605 ICVD cases were matched for sex and 1-year age strata with 1210 controls free of IVD from the CGPS.
Genotyping
To genotype for the exact number of gene copies of GSTM1 and GSTT1 in all studies, we used a high-throughput, real-time polymerase chain reaction method previously developed and described by us in detail. 37 From the GSTM1 and GSTT1 genotypes, we generated all 9 possible genotype combinations (GSTM1 plus GSTT1 genotype combinations as follows: *1/1 plus *1/1, *1/0 plus *1/1, *1/1 plus *1/0, *0/0 plus *1/1, *1/0 plus *1/0, *1/1 plus *0/0, *0/0 plus *1/0, *1/0 plus *0/0, *0/0 plus *0/0 ( Figures 1 through 3 ). Finally, we collapsed these combinations into 5 genotype groups based on counting the total number of GST gene copies, assuming an additive effect of the 2 genes (4 gene copies: *1/1 plus *1/1; 3 gene copies: *1/0 plus *1/1, *1/1 plus *1/0; 2 gene copies: *0/0 plus *1/1, *1/0 plus *1/0, *1/1 plus *0/0; 1 gene copy: *0/0 plus *1/0, *1/0 plus *0/0; 0 gene copies, *0/0 plus *0/0). The GSTP1 Ile105Val (rs1695) and Ala114Val (rs1138272) variants, located in the substrate-binding site of this enzyme, were genotyped in the CCHS by TaqMan.
Biochemical Analyses
Total cholesterol, low-density lipoprotein (LDL) cholesterol, highdensity lipoprotein cholesterol, triglycerides, fibrinogen, and white blood cell (WBC) count were measured using standard hospital assays (Boehringer-Mannheim GmbH; Mannheim, Germany; or Konelab; Helsinki, Finland). LDL cholesterol was calculated using the Friedewald equation 38 if triglyceride levels were Ͻ4 mmol/L but measured directly at higher triglyceride levels. High-sensitivity C-reactive protein (CRP) was measured by turbidimetry (DAKO; Glostrup, Denmark). Plasma levels of YKL-40 and oxidized LDL were measured by ELISA (Quidel Corp; San Diego, CA; or Mercodia AB, Uppsala, Sweden).
Other Covariates
Diabetes mellitus, smoking, alcohol consumption, and hypertension were dichotomized and defined as diabetes (self-reported disease, use of insulin, use of oral hypoglycemic drugs, and nonfasting plasma glucose Ͼ11.0 mmol/L (Ͼ200 mg/L), ever smokers (exsmoker or current smoker), heavy drinkers (defined as drinking Ͼ36 g alcohol per week or drinking more than once a week), or use of antihypertensive therapy. Body mass index was measured as weight (kg) divided by height squared (m 2 ). Use of statins also included use of other lipid-lowering drugs. Pack-years of smoking history was the maximum accumulated smoking exposure calculated from the questionnaires and categorized as 0 pack-years (nonsmokers and smokers having smoked 1 pack of cigarettes per day for Ͻ1 year), Ͻ25 pack-years (smokers having smoked 1 pack of cigarettes per day for a period between 1 and 25 years), and Ն25 pack-years (smokers having smoked 1 pack of cigarettes per day for Ն25 years).
Statistical Analysis
Data were analyzed using STATA/S.E. version 10.0. Two-sided PϽ0.05 was considered significant, with the exception of power Nørskov et al CNV in GSTM1 and -T1 and Ischemic Vascular Disease calculations. For power calculations, 1-sided PϽ0.05 was considered significant because of the prior assumption of a risk increase associated with the null allele of the GST genes. We used Mann-Whitney U test and Pearson 2 test. For trend tests, subjects classified according to GST genotype, genotype combinations, or number of gene copies were coded as 1, 2, 3, and so forth, ranked according to decreasing number of gene copies. In the prospective CCHS, with the use of left truncation and delayed entry, Cox proportional hazards regression models with age as time scale were used to estimate hazard ratios (HRs) for IHD, MI, ICVD, and IS as a function of GST genotypes or genotype combinations. In the cross-sectional CGPS, in the 2 case-control studies (CIHDS and CCSS), and in all studies combined, logistic regression or conditional logistic regression (case-control studies) was used to estimate odds ratios (ORs). Multifactorial adjustment included the risk factors of sex, age, total cholesterol, LDL cholesterol, highdensity lipoprotein cholesterol, triglycerides, body mass index, antihypertensive therapy, diabetes mellitus, smoking, alcohol intake, lipid-lowering therapy, menopausal status, and hormonal replacement therapy as time-dependent covariates for the prospective CCHS and as values at study entry for all other studies. Bivariate interaction terms between GST genotype and smoking categories (pack-years) were included in the respective models for CCHS and CGPS and were tested statistically by a likelihood ratio test. The proportional hazards assumption for Cox regression was tested graphically by plotting Ϫln[Ϫln(survival probability)] versus ln(analysis time) for all comparisons; no violations were observed.
Levels of high-sensitivity CRP, fibrinogen, WBC count, and YKL-40 were adjusted for age, sex, body mass index, smoking, and study by linear regression. Levels of CRP also were adjusted for CRP genotype. 34 Bivariate interaction terms between GST genotype and smoking categories on levels of inflammatory markers were included in the linear regression model and were tested statistically by a likelihood ratio test. Plasma levels of CRP and YKL-40 were ln-transformed before analysis to obtain normal distributions.
Meta-Analyses
To summarize results from previous studies on the association between GSTM1 and GSTT1 genotype (*0/0 versus all other genotypes) and risk of IHD, 8 different meta-analyses were performed, 4 for each gene, as follows: 1 summarizing results for all studies, including the 3 studies from Copenhagen (CCHS, CGPS, CIHDS); 1 summarizing results for the 3 studies from Copenhagen alone; and 2 summarizing results for whites and nonwhites. Relevant peerreviewed articles were identified from meta-analyses published in 2010 39, 40 and by searching PubMed, EMBASE, and the Genetic Association Database until January 31, 2011. Compared with the previously published meta-analyses, we excluded 1 study 16 because it presented only genotype combinations and individual genotypes could not be extracted from the data. In the meta-analyses stratified in subgroups by ethnicity, we excluded 2 studies from Brazil 28, 29 because these studies included a mixture of whites, blacks, and mulattos, and data by ethnicity could not be extracted. I 2 statistics evaluated study heterogeneity. 41 Fixed-effects as well as randomeffects ORs were estimated; however, the random-effects model was the model of choice when heterogeneity between studies was present. 42
Results
Clinical characteristics of the participants in each study cohort by disease status are shown in Tables 1 and 2 . Genotype distributions in the general population (CCHS and CGPS, nϭ20 094) were 52% GSTM1*0/0, 40% GSTM1*1/0, and 8% GSTM1*1/1 and 15% GSTT1*0/0, 47% GSTT1*1/0, and 38% GSTT1*1/1 and were similar in the 2 studies (tests for Hardy-Weinberg equilibrium P values, 0.31 to 0.67). In all 4 studies, a total of 49 individuals carried 3 gene copies of either GSTM1 or GSTT1 (23 in CCHS, 17 in CGPS, 6 in CIHDS, 3 in CCSS) and were excluded from all further analyses.
GST CNV and Risk of IVD
Multifactorially adjusted HRs for IHD, MI, ICVD, or IS as a function of GSTM1 or GSTT1 genotype in the CCHS did not differ significantly from 1.0 for any of the individual genotypes or genotype combinations (P for trend, 0.31 to 0.97) (Figures 1 and 2) . These findings were confirmed in the CGPS (P for trend, 0.05 to 0.99), the CIHDS (P for trend, 0.41 to 0.95), and the CCSS (P for trend, 0.13 to 0.89). When genotype combinations were collapsed into 5 groups based on the total number of GST gene copies, similar P values were obtained (0.07 to 0.93) (data not shown). In the CCHS, homozygosity for the null alleles for both GST genes (ie, individuals with the GSTM1*0/0, GSTT1*0/0 genotype), was associated with an HR for IHD of 1.47 (95% CI, 1.05 to 2.06) ( Figure 1 ), a finding that could not be replicated for IHD or for any other ischemic end point in any of the 4 studies (Figures 1 and 2) .
Frequencies of ever smokers compared with never smokers were significantly increased for IHD and ICVD in all studies (Tables 1 and 2 ). Smoking (Ͻ25 and Ն25 pack-years versus 0 pack-years) was associated with HRs (age and sex adjusted) for IHD of 1.40 (95% CI, 1.21 to 1.61) and 1.74 (95% CI, 1.52 to 1.99) in the CCHS and 1.51 (95% CI, 1.26 to 1.81) and 2.02 (95% CI, 1.60 to 2.56) in the CGPS.
There were no significant interactions between GSTM1 or GSTT1 genotypes and smoking exposure (0, Ͻ25, Ն25 pack-years) on risk of IHD, MI, ICVD, or IS in the CCHS or in the CGPS (P for interaction, 0.11 to 0.91) (online-only Data Supplement Figures I and II). When data from both studies of the general population (CCHS plus CGPS) were combined to achieve the maximal statistical power (cases, nϭ3482; controls 15 512), there also was no interaction between smoking exposure and GSTM1 or GSTT1 genotypes on risk of any ischemic vascular event (P for interaction, 0.52 to 0.78) (online-only Data Supplement Figure III ).
GST CNV, Markers of Inflammation, and Lipid Peroxidation
GSTM1 or GSTT1 CNV alone or as genotype combinations did not associate with plasma levels of high-sensitivity CRP; fibrinogen; WBC count; or YKL-40, an inflammatory marker mainly produced by macrophages and neutrophils 43 (P for trend, 0.07 to 0.99) (online-only Data Supplement Figure IV) . When genotype combinations were collapsed into 5 groups based on the total number of GST gene copies, similar P values were obtained (0.11 to 0.58) (data not shown). Furthermore, GSTM1 or GSTT1 genotypes did not interact with smoking status on any of the inflammatory markers tested (data not shown). Finally, GSTM1 or GSTT1 CNVs did not associate with levels of oxidized LDL in a subsample of participants in the CCHS (P for trend, 0.51 to 0.80) (onlineonly Data Supplement Figure V) . 
GST CNV and Risk of Any Ischemic Vascular Event
When the data from all 4 studies (CCHS, CGPS, CIHDS, and CCSS) were combined to achieve maximal statistical power (cases, nϭ6557; controls, nϭ16 502), ORs for any ischemic vascular event as a function of CNV in GSTM1 or GSTT1 alone or combined did not differ significantly from 1.0, whether assuming a codominant mode of inheritance (gene dosage effect) as in our study or assuming a recessive mode of inheritance as in previous studies (null genotype [*0/0] versus all other genotypes [*1/0 plus *1/1]) (P values, 0.85 to 0.98) ( Figure 3) .
Finally, to examine the potential effect of the number of gene copies present and assuming an additive effect of gene copies from the GSTM1 and GSTT1 genes, we collapsed the 9 genotype combinations into 5 genotype groups based on the total number of gene copies. Compared with 4 gene copies, risk of any ischemic vascular event as a function of 3, 2, 1, and 0 gene copies did not differ significantly from 1.0 ( Figure  3 ). In the combined study, we had 90% power to detect ORs between 1.10 and 1.20 for most genotypes and genotype combinations (Figure 3) .
To demonstrate the validity of our data, we examined the well-established association between CNV in GSTM1 and risk of bladder cancer 44 in the CCHS study. The cumulative incidence of bladder cancer increased with decreasing GSTM1 copy numbers (log rank P for trend, 0.03). 45 Multifactorially adjusted HRs for bladder cancer were 1.5 (95% CI, 0.7 to 3.2) for GSTM1*1/0 and 2.0 (95% CI, 0.9 to 4.3) for GSTM1*0/0 versus GSTM1*1/1 (P for trend, 0.02) (Figure 3 ).
Meta-Analyses: GST CNV and Risk of IHD
In a meta-analysis combining 22 studies on risk of IHD, including the 3 studies from Copenhagen (13 196 cases and 33 228 controls), individuals with the GSTM1*0/0 versus other genotypes had a random-effects OR for IHD of 1.28 (95% CI, 1.03 to 1.59), with an I 2 of 95% (P for heterogeneity, Ͻ0.001), suggesting substantial heterogeneity between studies (Figure 4) . On exclusion of 1 study (nϭ1816) with a 44 The right column shows the lowest odds ratio that can be detected with a 1-sided PϽ0.05 with 90% statistical power. *Four gene copies (combined genotype 1ϭreference group), 3 gene copies (combined genotypes 2 to 3), 2 gene copies (combined genotypes 4 to 6), 1 gene copy (combined genotypes 7 to 8), 0 gene copies (combined genotype 9). Abbreviations as in Figure 1 .
very extreme OR of 9.05 (95% CI, 7.17 to 11.42), 22 the OR was no longer significant. In a meta-analysis combining 20 studies on risk of IHD, including the 3 studies from Copenhagen (cases, 12 494; controls, 32 088), individuals with the GSTT1*0/0 versus other genotypes had a random-effects OR of 1.20 (95% CI, 0.95 to 1.51) and an I 2 of 92% (P for heterogeneity Ͻ0.001) ( Figure 5 ). In meta-analyses, only including the 3 studies from Copenhagen (CCHS, CGPS, CIHDS), the fixed-and random-effects ORs for both GSTM1 and GSTT1 were similar at 0.97 (95% CI, 0.91 to 1.03) for GSTM1 (Figure 4 ) and 1.05 (95% CI, 0.96 to 1.15) for GSTT1 ( Figure 5 ). For both genes, I 2 was 0% (P for heterogeneity, 0.62 to 0.84), suggesting no heterogeneity among the Copenhagen studies. When stratifying by race/ethnicity, neither GSTM1*0/0 nor GSTT1*0/0 genotypes associated with risk of IHD in whites (GSTM1 OR, 1.06; 95% CI, 0.95 to 1.19; I 2 , 62%; GSTT1 OR, 1.06; 95% CI, 0.95 to 1.18; I 2 , 35%) (online-only Data Supplement Table I ). In nonwhites, I 2 was 98% (P for heterogeneity, Ͻ0.001), suggesting extreme heterogeneity between studies for both GSTM1 and GSTT1. Using randomeffects models, none of the ORs were significant (1.44 [95% CI, 0.66 to 3.17] and 1.29 [95% CI, 0.56 to 2.95], respectively) (online-only Data Supplement Table I ).
GSTP1 Genotypes and Risk of IVD and Markers of Inflammation
The genotype distributions for GSTP1 I105V (rs1695) and A114V (rs1138272) in the CCHS were as follows: 12% II homozygotes, 45% IV heterozygotes, and 43% noncarriers for I105V and 0.7% VV homozygotes, 15% AV heterozy-gotes, and 84% noncarriers for A114V (tests for Hardy-Weinberg equilibrium P values, 0.36 to 0.94).
In the CCHS, multifactorially adjusted HRs for IHD, MI, ICVD, or IS as a function of GSTP1 I105V or A114V genotypes, alone or as combined genotypes, did not differ consistently from 1.0 (P for trend, 0.01 to 0.85) (onlineonly Data Supplement Figure VI) . Although single point estimates based on few events and a single end point were significant, they were not replicated for other ischemic end points. Furthermore, after Bonferroni correction for multiple comparisons, none of these estimates remained significant.
There were no significant interactions between the GSTP1 I105V genotype or GSTP1 A114V genotype, alone or as combined genotypes, and smoking exposure (0, Ͻ25, Ն25 pack-years) on risk of IHD, MI, ICVD, or IS in the CCHS (P for interaction, 0.06 to 0.96) (online-only Data Supplement Figure VII ) (data not shown for combined genotypes).
GSTP1 genotypes alone or combined did not associate with plasma levels of CRP, fibrinogen, WBC count, or YKL-40 (P for trend, 0.40 to 0.94) (data not shown). Furthermore, GSTP1 genotypes also did not interact with smoking status on any of the inflammatory markers tested (P for interaction, 0.19 to 0.98) (data not shown).
Discussion
The principal findings of this study are that CNV in GSTM1 and GSTT1 is not associated with risk of IHD, MI, ICVD, IS, or any ischemic vascular event. The absence of an association between CNV in GSTM1 or GSTT1 and risk of IVD was consistently observed in 4 large studies, including 2 studies of the general population and 2 case-control studies comprising 6557 cases of IVD and 16 502 controls, and in meta-analyses comprising 13 196 cases of IHD and 33 228 controls. Furthermore, these associations were not affected by smoking exposure.
Previous studies investigating the association between CNV in GST genes and risk of IHD are mainly case-control studies incorporating a limited number of cases. 10 -32 Furthermore, these studies discriminated only between carriers (GST *1/0 plus *1/1 plus *1/2 genotypes) and noncarriers (GST *0/0 genotypes), and none investigated a gene dosage effect, the effect of genotype combinations, or the total number of gene copies on risk.
The GSTT1 genotype has been associated with cardiovascular disease risk in patients with diabetes in some studies, 27, 32 but not in others, 21 and with an interaction between genotype and smoking on cardiovascular disease. 21 Schwartz et al 46 found an interaction between fineparticulate air pollution and GSTM1 genotype on the high-frequency component of heart rate variability in 497 elderly individuals. However, these results obtained in persons with diabetes and elderly persons are not directly comparable to the results of the current studies, as in both the individuals studied, the exposure and the end points varied between studies.
The present study, which is substantially larger than previous studies, was able to exclude even small increases in the risk of IVD as a function of GST genotypes. For most comparisons, our analysis had 90% statistical power to exclude an OR for IVD between 1.10 and 1.20, thus effectively excluding the association observed in a previously published meta-analysis. 39, 40 Notably, when we reanalyzed our data using the traditional noncarrier (*0/0) versus carrier (all other genotypes) genotype classification, we also observed no association between GST genotypes and risk of any ischemic vascular event. Furthermore, the I105V and A114V variants in GSTP1 did not consistently associate with IVD in the CCHS, confirming results from previous studies. 11, 23, 32 Previous studies have suggested interaction between CNV in GSTM1 and GSTT1 and smoking on risk or severity of IHD. 11, 12, 17, 18, 20, 22, 24, 25, 27, 30, 32 Smoking is an established risk factor for IVD. In agreement with this, in the present studies, smoking exposure in pack-years associated with a stepwise increase in risk of IHD in both studies of the general population. We examined the interaction between GST genotypes and smoking exposure on risk of IHD, MI, ICVD, IS, and any ischemic vascular event in the CCHS and the CGPS, in which we had excellent information on accumulative smoking exposure. Smoking did not interact with GST genotypes on any ischemic end points in the studies individually or combined. Results were similar for the I105V and A114V variants in GSTP1.
Previous studies of association between GST genotype and levels of inflammatory markers or lipid peroxidation have shown conflicting results (nϽ1000 participants). 21, 47, 48 We found no association between GST CNVs or GSTP1 I105V or A114V genotypes, alone or in combination, with plasma levels of high-sensitivity CRP, fibrinogen, WBC count, or YKL-40 in Ͼ15 000 individuals from the general population without IVD and no effect of GST genotypes on levels of oxidized LDL in a subset of individuals from the CCHS. These results suggest that GST enzymes may not have enough impact on protection against inflammation to produce detectable effects on levels of markers of inflammation or lipid peroxidation. These observations were independent of smoking exposure.
The association between CNV in GSTM1 and GSTT1 and a stepwise decrease in enzyme activity has been shown in red blood cells for both genes, and across a variety of tissues for GSTT1. 8 It has not been shown directly that the null alleles actually change cardiac or coronary vascular GST activity. Assuming a change in activity, we cannot exclude a compensatory increase in expression of other GSTs in cardiovascular organs of M1 or T1 null genotypes, but this limitation of the present studies would pertain to other studies as well. Unlike humans, mice and rats do not possess the GST null genotypes. However, genetic variation in expression of Gstm1 in mice has been associated with differences in vascular smooth muscle cell proliferation, reactive oxygen species production, and cell migration in 1 study. 49 A recent meta-analysis suggested that the GSTM1*0/0 genotype associated with an increased risk of IHD (OR, 1.38; 95% CI, 1.01 to 1.87). 39, 40 Updated meta-analyses of risk of IHD as a function of GSTM1*0/0 and GSTT1*0/0 genotypes in all studies combined, including the 3 studies from Copenhagen (CCHS, CGPS, CIHDS), in studies of whites, and in studies of nonwhites showed moderate to extreme heterogeneity among studies. Using the random-effects model, none of the meta-analyses showed an association of GST*0/0 genotype with risk of IHD, with the exception of the meta-analysis of all studies for GSTM1. However, this result was driven by a very extreme OR in a moderate-sized study and became insignificant when this outlier was removed. Thus, although genotype frequencies are known to differ between whites and other races/ethnicities for CNV in GST genes, 50 the ORs for IHD did not differ among races/ ethnicities and were insignificant for both GST genes in whites and nonwhites. Finally, in contrast to the results of the updated meta-analyses, the meta-analyses of the 3 studies from Copenhagen showed no signs of heterogeneity among studies, and CNV in GST genes did not associate with risk of IHD. Taken together, these results suggest that CNV in GST genes does not associate with risk of IVD.
We were able to validate the well-established association between CNV in GSTM1 and risk of bladder cancer, 44, 45 demonstrating the power of our study design. A limitation was that we studied only whites, and therefore, our results may not apply to other races or ethnic groups.
In conclusion, in 4 large studies and in meta-analyses, CNV in GSTM1 and GSTT1 did not associate with risk of IHD, MI, ICVD, IS, or any ischemic vascular event. Additionally, we detected no interaction between GST CNV and smoking exposure on risk.
